#gene therapy

3개의 글

July 7, 2026

Sarepta Therapeutics (SRPT) Stock Outlook 2026: ELEVIDYS Gene Therapy and the Biotech Binary Risk

Sarepta Therapeutics (SRPT) Stock Outlook 2026 covering the ELEVIDYS DMD gene therapy, the 2025 patient-death safety events and FDA scrutiny that crushed the stock, the exon-skipping revenue base, RNA and gene-therapy pipeline, binary biotech risk, peer comparison and what global investors should weigh on tax, currency and dilution.

Sarepta SRPT US Stocks

July 6, 2026

BEAM (Beam Therapeutics) Stock Outlook 2026: The Next Generation of Base-Editing Gene Therapy

BEAM Beam Therapeutics stock outlook 2026. Base editing technology moat, BEAM-101 sickle cell and beta-thalassemia pipeline, CRSP and NTLA competition, clinical binary risk, cash runway, and a practical positioning framework for investors.

BEAM Beam Therapeutics base editing

May 12, 2026

VRTX Vertex Pharmaceuticals Stock Outlook 2026: Beyond Trikafta — Three New Bets Ramp

VRTX Vertex Pharmaceuticals stock outlook 2026. Trikafta $2.35B quarterly revenue, Journavx non-opioid pain FDA approved January 30 2025, Casgevy gene therapy 9 countries, inaxaplin APOL1 kidney interim data expected early 2027. Three-scenario valuation for US investors.

VRTX Vertex Pharmaceuticals Trikafta